AgomAb Therapeutics (NASDAQ:AGMB) Trading Up 9.6% – Time to Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price traded up 9.6% during trading on Monday . The stock traded as high as $15.20 and last traded at $15.13. Approximately 40,410 shares traded hands during trading, a decline of 72% from the average session volume of 141,930 shares. The stock had previously closed at $13.81.

Wall Street Analyst Weigh In

Several brokerages have commented on AGMB. HC Wainwright initiated coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Leerink Partners began coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 price objective for the company. Finally, Morgan Stanley assumed coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.75.

AgomAb Therapeutics Trading Down 0.3%

The business’s fifty day moving average price is $11.35.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.